Beta-cell sparing in transplanted islets by vascular endothelial growth factor

Area of Science:

• * Regenerative Medicine
• * Immunology
• * Endocrinology

Background:

• * Vascular Endothelial Growth Factor (VEGF) is known to promote revascularization of transplanted islets, reducing the number needed for diabetes prevention.
• * Further investigation into other beta-cell sparing mechanisms of VEGF is warranted.

Purpose of the Study:

• * To assess additional mechanisms by which VEGF spares beta-cells in islet transplantation.
• * To evaluate the effects of VEGF on islet viability, necrosis, and apoptosis in vitro and in vivo.
• * To examine the impact of VEGF on islet oxygenation, immune rejection, and overall function post-transplantation.

Main Methods:

• * In vitro: Islets cultured with/without VEGF (20 ng/mL) for 14 days; assessed viability, necrosis, apoptosis using specific stains.
• * Proteomic analysis of VEGF-treated islets.
• * In vivo: Streptozotocin-diabetic Lewis rats received syngeneic or allogeneic islets under the renal capsule.
• * Monitored oxygen levels at transplant site and fasting blood glucose.
• * Assessed allograft rejection and performed immunostaining for MHC II antigen.

Main Results:

• * VEGF significantly enhanced oxygen levels at the transplant site.
• * Syngeneic islet grafts in VEGF-treated recipients remained functional for over 6 months; controls failed within 30-60 days.
• * VEGF delayed allograft rejection by over 14 days compared to 6-7 days for controls.
• * VEGF inhibited MHC II antigen presentation, necrosis, and apoptosis, preserving islet cells.
• * Proteomic data indicated VEGF preserved heat shock proteins and insulin secretion systems.

Conclusions:

• * VEGF promotes isolated and transplanted islet preservation through multiple mechanisms.
• * Enhanced oxygenation and inhibition of immune rejection, necrosis, and apoptosis are key effects.
• * Exogenous VEGF shows potential as an adjunct therapy for islet transplantation to improve outcomes.